phrykt

Beta Bionics, Inc. (BBNX): who owns it and who trades it

As of Nov 16, 2026, BBNX insiders reported 54 open-market sales worth $5.4M and no purchases in the last 12 months, with 72% of the sale value made under pre-set 10b5-1 plans. The largest seller was Mark Hopman (Chief Commercial Officer), with $2.3M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Beta Bionics

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns BBNX

131 funds and institutions reported BBNX shares worth $757M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Eventide Asset Management, LLC with 14.0%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Eventide Asset Management, LLC14.0%
Soleus Capital Management, L.P.9.9%
Morgan Stanley9.6%
Sands Capital Alternatives, LLC8.3%
BlackRock, Inc.7.5%
Point72 Asset Management, L.P.5.1%
Vanguard Capital Management LLC4.0%
Vestal Point Capital, LP3.6%
Rtw Investments, LP3.4%
Deerfield Management Company, L.P.3.0%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Eventide Asset Management, LLC6.25M14.03%$98.1M+5%
Soleus Capital Management, L.P.4.39M9.86%$68.8M+1%
Morgan Stanley4.27M9.58%$66.9M+1%
Sands Capital Alternatives, LLC3.71M8.32%$58.1MNo change
BlackRock, Inc.3.34M7.50%$52.3M+10%
Point72 Asset Management, L.P.2.25M5.06%$35.3M-11%
Vanguard Capital Management LLC1.78M4.00%$27.9M+3%
Vestal Point Capital, LP1.60M3.59%$25.1M-28%
Rtw Investments, LP1.50M3.37%$23.5M-25%
Deerfield Management Company, L.P.1.32M2.97%$20.7MNo change
Omega Fund Management, LLC1.32M2.95%$20.6MNo change
Eversept Partners, LP1.25M2.80%$19.6M-12%
Divisadero Street Capital Management, LP1.11M2.50%$17.5M–
Geode Capital Management, LLC1.07M2.41%$16.8M+15%
State Street Corp970,1922.18%$15.2M+3%
Millennium Management LLC956,2442.15%$15M+11%
Balyasny Asset Management L.P.855,6821.92%$13.4M+38%
Perceptive Advisors LLC832,9441.87%$13.1M-1%
JPMorgan Chase & Co703,3561.58%$12M–
Bruce & Co., Inc.665,7001.49%$10.4M+21%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, BBNX insiders reported $0 of open-market purchases and $5.4M of sales. 72% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$5.4M
54 trades, 8 people
Sales under a 10b5-1 plan
72%
Share of sale value
Latest trade
Nov 11, 2026
Filed Nov 13, 2026

Purchases and sales by month

$3M$3MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 11, 2026Stephen FeiderCFOSale plan8,874$17.21$153KForm 4
Nov 9, 2026Stephen FeiderCFOSale plan744$17.00$12.6KForm 4
Nov 5, 2026Stephen FeiderCFOSale plan382$17.04$6.5KForm 4
Nov 2, 2026Mark HopmanChief Commercial OfficerSale plan370$16.90$6.3KForm 4
Oct 27, 2026Mike MensingerChief Product OfficerSale plan2,650$22.00$58.3KForm 4
Oct 26, 2026Mark HopmanChief Commercial OfficerSale plan821$20.00$16.4KForm 4
Oct 14, 2026Mark HopmanChief Commercial OfficerSale775$17.35$13.4KForm 4
Oct 1, 2026Mark HopmanChief Commercial OfficerSale370$18.96$7KForm 4
Sep 22, 2026Christy JonesDirectorSale plan6,430$23.00$148KForm 4
Sep 16, 2026Mark HopmanChief Commercial OfficerSale plan30,779$20.13$620KForm 4
Sep 16, 2026Mike MensingerChief Product OfficerSale plan2,650$22.00$58.3KForm 4
Sep 14, 2026Mark HopmanChief Commercial OfficerSale plan775$15.52$12KForm 4
Sep 9, 2026Mark HopmanChief Commercial OfficerSale plan35,994$18.46$664KForm 4
Sep 9, 2026Mark HopmanChief Commercial OfficerSale plan36,870$18.46$681KForm 4
Sep 3, 2026Sean SaintCEOSale plan5,641$20.08$113KForm 4
Sep 2, 2026Mark HopmanChief Commercial OfficerSale5,327$19.11$102KForm 4
Sep 2, 2026Steven Jon RussellChief Medical OfficerSale4,221$19.11$80.7KForm 4
Sep 2, 2026Mike MensingerChief Product OfficerSale4,375$19.11$83.6KForm 4
Sep 2, 2026Stephen FeiderCFOSale6,675$19.11$128KForm 4
Sep 2, 2026Sean SaintCEOSale16,867$19.11$322KForm 4
Jun 29, 2026Stephen FeiderCFOSale plan4,896$17.03$83.4KForm 4
Jun 26, 2026Stephen FeiderCFOSale plan5,104$17.05$87KForm 4
Jun 24, 2026Mark HopmanChief Commercial OfficerSale plan1,258$15.01$18.9KForm 4
Jun 24, 2026Christy JonesDirectorSale plan1,406$15.00$21.1KForm 4
Jun 4, 2026Mark HopmanChief Commercial OfficerSale plan275$12.31$3.4KForm 4
Jun 4, 2026Christy JonesDirectorSale plan2,811$14.00$39.4KForm 4
Jun 2, 2026Mike MensingerChief Product OfficerSale4,378$12.61$55.2KForm 4
Jun 2, 2026Mark HopmanChief Commercial OfficerSale5,329$12.61$67.2KForm 4
Jun 2, 2026Steven Jon RussellChief Medical OfficerSale4,222$12.61$53.2KForm 4
Jun 2, 2026Stephen FeiderCFOSale6,676$12.61$84.2KForm 4
Jun 2, 2026Sean SaintCEOSale16,872$12.61$213KForm 4
May 22, 2026Adam LezackDirectorSale plan998$11.21$11.2KForm 4
May 21, 2026Christy JonesDirectorSale plan1,998$9.95$19.9KForm 4
May 21, 2026Adam LezackDirectorSale plan1,000$9.95$9.9KForm 4
Mar 4, 2026Mark HopmanChief Commercial OfficerSale plan353$11.57$4.1KForm 4
Mar 2, 2026Mark HopmanChief Commercial OfficerSale834$12.36$10.3KForm 4
Mar 2, 2026Steven Jon RussellChief Medical OfficerSale1,026$12.36$12.7KForm 4
Mar 2, 2026Mike MensingerChief Product OfficerSale1,064$12.36$13.2KForm 4
Mar 2, 2026Stephen FeiderCFOSale1,428$12.36$17.7KForm 4
Mar 2, 2026Sean SaintCEOSale3,384$12.36$41.8KForm 4
Jan 6, 2026Mike MensingerChief Product OfficerSale plan2,200$30.10$66.2KForm 4
Jan 2, 2026Mike MensingerChief Product OfficerSale plan7,200$29.56$213KForm 4
Jan 2, 2026Mike MensingerChief Product OfficerSale plan600$30.20$18.1KForm 4
Jan 2, 2026Stephen FeiderCFOSale plan20,000$29.53$591KForm 4
Dec 4, 2025Mark HopmanChief Commercial OfficerSale plan2,061$30.66$63.2KForm 4
Dec 2, 2025Mark HopmanChief Commercial OfficerSale plan856$29.34$25.1KForm 4
Dec 2, 2025Steven Jon RussellChief Medical OfficerSale1,025$29.34$30.1KForm 4
Dec 2, 2025Mike MensingerChief Product OfficerSale1,063$29.34$31.2KForm 4
Dec 2, 2025Stephen FeiderCFOSale1,427$29.34$41.9KForm 4
Dec 2, 2025Sean SaintCEOSale3,278$29.34$96.2KForm 4
Dec 1, 2025Adam LezackDirectorSale plan906$29.35$26.6KForm 4
Dec 1, 2025Adam LezackDirectorSale plan500$29.91$15KForm 4
Dec 1, 2025Maria PalasisDirectorSale plan906$29.33$26.6KForm 4
Dec 1, 2025Maria PalasisDirectorSale plan500$29.96$15KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Mark HopmanChief Commercial Officer–$2.3MNov 2, 2026
Stephen FeiderChief Financial Officer–$1.2MNov 11, 2026
Sean SaintPresident & CEO, Director–$786KSep 3, 2026
Mike MensingerChief Product Officer–$597KOct 27, 2026
Christy JonesDirector–$228KSep 22, 2026
Steven Jon RussellChief Medical Officer–$177KSep 2, 2026
Adam LezackDirector–$62.7KMay 22, 2026
Maria PalasisDirector–$41.6KDec 1, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

BBNX short interest

Moderate short interest. 9.2% of BBNX shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went down 12%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 4.98M BBNX shares were sold short, 9.2% of the shares outstanding, down 28.0% from the report before. At the average daily volume of 1.27M shares, buying them all back would take about 3.9 trading days (days to cover).

Shares short, % of all shares

9.16%May 15Oct 3025.8%

Days to cover

3.9May 15Oct 3010.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20264.98M9.16%-28%1.27M3.9
Oct 15, 20266.92M15.37%+14%936,7557.4
Sep 30, 20266.05M13.44%-43%1.86M3.2
Sep 15, 202610.62M23.60%+13%1.07M9.9
Aug 31, 20269.40M20.90%+25%1.04M9.0
Aug 14, 20267.49M16.66%-1%1.37M5.5
Jul 31, 20267.60M16.90%+15%1.26M6.0
Jul 15, 20266.61M14.83%-3%948,7087.0
Jun 30, 20266.82M15.30%+46%1.16M5.9
Jun 15, 20264.67M10.49%-10%1.04M4.5
May 29, 20265.20M11.67%-9%721,0947.2
May 15, 20265.69M12.76%-8%624,5279.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Beta Bionics company events

Beta Bionics filed 10 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Oct 27, 2026.

  1. Oct 27, 2026ResultsReleased financial results. Filing
  2. Sep 17, 2026AnnouncementBeta Bionics, Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC, Piper Sandler & Co., Wells Fargo Securities, LLC and Leerink Partners LLC, as representatives of the several underwriters named therein, relating to the issuance and sale in a public offering of 7,652,175… Filing
  3. Sep 15, 2026AnnouncementWe announced FDA clearance of Mint, our patch pump featuring a transformative reusable and disposable architecture that does not require recharging, integrates with industry-leading continuous glucose monitors (CGM) and enables smartphone control for iOS and Android users. Filing
  4. Jul 29, 2026ResultsReleased financial results. Filing
  5. May 22, 2026VoteReported shareholder vote results. Filing
  6. May 21, 2026AnnouncementThe Company announced that it expects to fully commercialize Mint by the end of the second quarter of 2027, subject to regulatory clearance by the U.S. Food and Drug Administration. Filing
  7. Apr 21, 2026ResultsReleased financial results. Filing
  8. Feb 17, 2026ResultsReleased financial results. Filing
  9. Jan 30, 2026AnnouncementBeta Bionics, Inc. received a warning letter from the U.S. Food and Drug Administration following inspection of the Company’s facility in Irvine, California that occurred from June 9, 2025 through June 26, 2025. Filing
  10. Jan 8, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Beta Bionics financials

Famous investors that hold BBNX

5 of the 50 well-known investors we track reported holding BBNX in their latest 13F filing. The largest position is Steve Cohen's, worth $18.4M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 2026967,144$18.4M0.0%-57%
Paul Tudor Jones · Tudor Investment CorpQ3 2026187,803$3.6M0.0%+194%
Ken Griffin · Citadel AdvisorsQ3 2026103,450$2M0.0%New
Jim Simons · Renaissance TechnologiesQ3 202661,600$1.2M0.0%+445%
Israel Englander · Millennium ManagementQ3 202615,915$302K0.0%-98%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named BBNX in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Point72 Asset Management, L.P.13G/A1.8%
Nov 16, 2026Divisadero Street Capital Management, LP13G/A0.1%
Nov 16, 2026Divisadero Street Capital Management, LP13G/A0.1%
Nov 16, 2026Point72 Asset Management, L.P.13G/A1.8%
Nov 9, 2026Soleus Private Equity Fund II, L.P.13G/A1.8%
Nov 9, 2026Soleus Private Equity Fund II, L.P.13G/A1.8%
Oct 7, 2026T. Rowe Price Associates, Inc.13G16.6%
Oct 7, 2026T. Rowe Price Associates, Inc.13G16.6%

Questions about Beta Bionics, Inc. (BBNX) stock

Who owns the most BBNX stock?

The largest reported owner of Beta Bionics, Inc. (BBNX) is Eventide Asset Management, LLC, with 14.0% of the company. In total, 131 funds and institutions reported holding BBNX at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are BBNX insiders buying or selling?

In the last 12 months, BBNX insiders reported no open-market purchases and 54 sales worth $5.4M. The latest trade was on Nov 11, 2026. See every trade.

What is the short interest in BBNX?

As of Oct 30, 2026, 4.98M BBNX shares were sold short, 9.2% of the shares outstanding, down 28.0% from the report before. At the average daily volume of 1.27M shares, buying them all back would take about 3.9 trading days (days to cover). See the history.

Which famous investors hold BBNX?

5 of the 50 well-known investors we track reported BBNX in their latest 13F filing, including Steve Cohen, Paul Tudor Jones, Ken Griffin. The largest position is worth $18.4M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.